Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK 3 Inhibitor IX (6-BIO) 是一种选择性可逆的,ATP 竞争性的 GSK-3α/β和 CDK1-cyclinB 复合体抑制剂,能够抑制 (GSK-3α/β)/CDK1/CDK5 的活性,IC50值分别为 5 nM/320 nM/83 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 258 | 现货 | ||
2 mg | ¥ 362 | 现货 | ||
5 mg | ¥ 651 | 现货 | ||
10 mg | ¥ 897 | 现货 | ||
25 mg | ¥ 1,960 | 现货 | ||
50 mg | ¥ 3,570 | 现货 | ||
100 mg | ¥ 5,160 | 现货 | ||
500 mg | ¥ 10,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 719 | 现货 |
产品描述 | GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity with IC50 values of 5 nM/320 nM/83 nM, respectively. |
靶点活性 | TYK2:30 nM, CDK2-CyclinA:0.30 μM, CDK1-CyclinB:0.32 μM, GSK-3:5 nM, CDK5-p35:0.08 μM |
体外活性 | BIO抑制小鼠移植瘤模型中黑色素瘤生长. |
体内活性 | BIO是pan-JAK抑制剂,作用于TYK2,JAK1,JAK2 和 JAK3,IC50值分别为0.03,1.5,8.0,0.5 μM。BIO是糖原合成酶激酶-3(GSK-3)的特异性抑制剂,GSK-3α/β的IC50为5 nM,比CDK5选择性高16倍以上。BIO与这些激酶的ATP结合口袋相互作用,减少细胞模型中GSK-3特异性位点上的β-连环蛋白磷酸化。BIO促进哺乳动物心肌细胞增殖。BIO选择性抑制STAT3磷酸化,并诱导人类黑色素瘤细胞凋亡。在人类和小鼠胚胎干细胞中,BIO维持未分化表型并维持多能状态特异性转录因子Oct-3/4,Rex-1和Nanog的表达。 |
激酶实验 | Kinase assay: Kinase activities are assayed in Buffer A or C at 30°C, at a final ATP concentration of 15 μM. Blank values are subtracted and activities calculated as pmoles of phosphate incorporated during a 10 min incubation. Controls are performed with appropriate dilutions of dimethylsulfoxide. In a few cases phosphorylation of the substrate is assessed by autoradiography after SDS-PAGE. GSK-3α/β is purified from porcine brain by affinity chromatography on immobilized axin. It is assayed, following a 1/100 dilution in 1 mg BSA/ml 10 mM DTT, with 5 μl 40 μM GS-1 peptide, a specific GSK-3 substrate, (YRRAAVPPSPSLSRHSSPHQSpEDEEE), in buffer A, in the presence of 15 μM [γ-32P] ATP (3,000 Ci/mmol; 1 mCi/ml) in a final volume of 30 μl. After 30 min incubation at 30°C, 25 μl aliquots of supernatant are spotted onto 2.5 × 3 cm pieces of Whatman P81 phosphocellulose paper, and 20 seconds later, the filters are washed five times (for at least 5 min each time) in a solution of 10 ml phosphoric acid/liter of water. The wet filters are counted in the presence of 1 ml ACS scintillation fluid. |
细胞实验 | COS1, Hepa (wild-type, CEM/LM AhR deficient and ELB1 ARNT deficient), or SH-SY5Y cells are grown in 6 cm culture dishes in Dulbecco's Modified Medium (DMEM) containing 10% fetal bovine serum. For treatment, IO (5 μM), BIO (5 or 10 μM), MeBIO (5 or 50 μM), LiCl (20 or 40 mM), or mock solution (DMSO, 0.5% final concentration) is added to medium when cell density reaches ~70% confluence. After 12 (SH-SY5Y) or 24 hours, the cells, while still in plate, are lysed with lysis buffer (1% SDS, 1 mM sodium orthovanadate, 10 mM Tris [pH 7.4]). The lysate is passed several times through a 26 g needle, centrifuged at 10,000 × g for 5 min, and adjusted to equal protein concentration. About 8 μg of each sample is loaded for immunoblotting. Enhanced chemiluminescence is used for detection. The following primary antibodies are used: mouse anti-β-catenin CT (Upstate Biotechnolgies, Clone 7D8, recognizes total β-catenin), mouse anti-phospho-β-catenin (Upstate Biotechnologies, Clone 8E7, recognizes dephosphorylated β-catenin), mouse anti-GSK-3 β, mouse anti-GSK-3 phosphoTyr216, rabbit anti-AhR (Aryl hydrocarbon receptor), and rabbit anti-actin.(Only for Reference) |
别名 | BIO, GSK 3 IX, 6-BIO, 6-Bromoindirubin-3'-oxime, MLS 2052, 6-bromoindirubin-3-oxime |
分子量 | 356.17 |
分子式 | C16H10BrN3O2 |
CAS No. | 667463-62-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (126.34 mM)
Ethanol: 21 mg/mL (58.96 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.8076 mL | 14.0382 mL | 28.0765 mL | 70.1912 mL |
5 mM | 0.5615 mL | 2.8076 mL | 5.6153 mL | 14.0382 mL | |
10 mM | 0.2808 mL | 1.4038 mL | 2.8076 mL | 7.0191 mL | |
20 mM | 0.1404 mL | 0.7019 mL | 1.4038 mL | 3.5096 mL | |
50 mM | 0.0562 mL | 0.2808 mL | 0.5615 mL | 1.4038 mL | |
DMSO | 100 mM | 0.0281 mL | 0.1404 mL | 0.2808 mL | 0.7019 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GSK 3 Inhibitor IX 667463-62-9 Apoptosis Cell Cycle/Checkpoint PI3K/Akt/mTOR signaling Stem Cells Tyrosine Kinase/Adaptors GSK-3 Tyrosine Kinases CDK BIO GSK 3 IX Cyclin dependent kinase Inhibitor Glycogen synthase kinase-3 Glycogen synthase kinase 3 MLS-2052 MLS2052 6-BIO 6-Bromoindirubin-3'-oxime inhibit MLS 2052 6-bromoindirubin-3-oxime inhibitor